]>
IRCT20140921019240N4 IRCT 2018-06-08 Sabzevar University of Medical Sciences Comparing two different doses of Atorvastatin for decrease the level of LDL in ACS patient. Comparing two different doses of Atorvastatin for decrease the level of LDL in ACS patient and determinate the effective dose of drug. 2018-06-22 anticipated 60 Complete https://irct.ir/trial/30169 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization From the beginning of the study, the names of the patients will be document in the table. The patients with odd number will be in A group and the patients with even number will be in B group, Blinding description: In this one-blind clinical trial, only subjects were unaware of the study procedure. 3 acute coronary syndrome. Intervention 1: Intervention group: The intervention group received three months of treatment with 40 mg of atorvastatin daily from the start of study. Atorvastatin product by Abidi Pharmaceutical Company. Intervention 2: Control group: The control group will be treated with atorvastatin 80 mg daily for three months. Atorvastatin product by Abidi Pharmaceutical Company. Yes - There is a plan to make this available What will be shared: After unidentifiable people, you can shared the all of personal data. When: The start of access period is 6 months after publish results. To whom: Researchers working in academic and scientific institutions and industry workers. Conditions: Using the results of this study with the source is allowed. Where to obtain: Dr.Omid Gholami Sabzevar University of Medical Science omid693@yahoo.com How to obtain: We can submit data if a person withe specific organizational affiliation, submit a written request. Comments:
public Nafiseh Khalilzadeh
Sabzevar University Of Medical Science
Sabzevar Iran (Islamic Republic of) 9617913112 +98 51 4466 4986 nafisekh31@yahoo.com Sabzevar University of Medical Sciences scientific Omid Gholami
Sabzevar University of Medical Science
Sabzevar Iran (Islamic Republic of) 9617913112 +98 51 4401 1320 omid693@yahoo.com Sabzevar University of Medical Sciences Iran (Islamic Republic of) َACS (acute coronary syndrom) patients who are admit in CCU (coronary care unit) in Heshmatie hospital no limit 75 years Both The normal coronary patients The patients who are more than 75 years old The patients who are using Fibrate drugs in the same time The patients who are living in the villages and disable for follow up I24.9 Acute ischemic heart disease, unspecified Treatment - Drugs Treatment - Drugs Intervention group: The intervention group received three months of treatment with 40 mg of atorvastatin daily from the start of study. Atorvastatin product by Abidi Pharmaceutical Company. Control group: The control group will be treated with atorvastatin 80 mg daily for three months. Atorvastatin product by Abidi Pharmaceutical Company. Low density lipoprotein. Timepoint: At the start of study & 3 months later. Method of measurement: Blood test. MDR1 (Multi-Drug Resistance ) gene polymorphism. Timepoint: At the start of study. Method of measurement: Polymerase Chain Reaction. Sabzevar University of Medical Sciences Approved 2018-02-26 Ethics committee of Sabzevar University of Medical Sciences Ethics committee of Sabzevar University of Medical Sciences, Shohadaie Hastehi Blvd, Sabzevar Sabzevar Razavi Khorasan Iran (Islamic Republic of)